Glen Eagle Advisors’s Krystal Biotech KRYS Stock Holding History

Glen Eagle Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.86K	Hold	5	–	–	﹤0.01%	902
2026 Q1	$1.29K	Hold	5	–	–	﹤0.01%	896
2025 Q4	$1.23K	Hold	5	–	–	﹤0.01%	945
2025 Q3	$883	Hold	5	–	–	﹤0.01%	1011
2025 Q2	$687	Hold	5	–	–	﹤0.01%	963
2025 Q1	$902	Hold	5	–	–	﹤0.01%	943
2024 Q4	$783	Hold	5	–	–	﹤0.01%	994
2024 Q3	$910	Hold	5	–	–	﹤0.01%	1016
2024 Q2	$918	Buy	+5	New	+$839	﹤0.01%	1009

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Glen Eagle Advisors's KRYS Position: Q2 2026 in Review

Glen Eagle Advisors held its Krystal Biotech (KRYS) position steady in Q2 2026 at 5 shares worth $1.86K. The position accounts for ﹤0.01% of the portfolio, ranked #902.

Glen Eagle Advisors first reported a position in KRYS in Q2 2024 and has held it in 9 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Glen Eagle Advisors held 5 shares of Krystal Biotech worth $1.86K as of Q2 2026.
Glen Eagle Advisors left its Krystal Biotech share count unchanged in Q2 2026.
Krystal Biotech made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q2 2026, its #902 holding.
Glen Eagle Advisors first reported a position in Krystal Biotech in Q2 2024 and has held it in 9 quarters since.
424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Glen Eagle Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.